We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
176
Inogen
INGN
$138M
– –
-125
Closed -$8K
IRIX icon
177
IRIDEX
IRIX
$11.1M
– –
-21,885
Closed -$308K
IVV icon
178
iShares Core S&P 500 ETF
IVV
$837B
$0 ﹤0.01%
1
– –
IWS icon
179
iShares Russell Mid-Cap Value ETF
IWS
$15.2B
$0 ﹤0.01%
2
– –
JNJ icon
180
Johnson & Johnson
JNJ
$644B
– –
-2
Closed –
LLY icon
181
CALL
Eli Lilly
LLY
$1.01T
– –
-100,000
Closed -$3K
MOH icon
182
Molina Healthcare
MOH
$10.8B
– –
-6,981
Closed -$379K
NTLA icon
183
Intellia Therapeutics
NTLA
$1.59B
– –
-14,673
Closed -$192K
NVAX icon
184
Novavax
NVAX
$1.52B
– –
-16,771
Closed -$423K
PBYI icon
185
Puma Biotechnology
PBYI
$477M
– –
-7,344
Closed -$225K
PFE icon
186
Pfizer
PFE
$157B
– –
-57,970
Closed -$1.79M
HIND
187
Vyome Holdings
HIND
$14.1M
– –
0
– –
SCYX icon
188
SCYNEXIS
SCYX
$43.7M
– –
-2,140
Closed -$546K
SGMO
189
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-272
Closed -$1K
DCOY
190
Decoy Therapeutics
DCOY
$1.78M
– –
0
– -$1K
SRPT icon
191
PUT
Sarepta Therapeutics
SRPT
$2.19B
– –
-10,900
Closed -$249K
SUPN icon
192
Supernus Pharmaceuticals
SUPN
$2.4B
– –
-421
Closed -$11K
TMO icon
193
Thermo Fisher Scientific
TMO
$237B
– –
-2
Closed –
UTHR icon
194
United Therapeutics
UTHR
$21.5B
– –
-4,753
Closed -$682K
VCEL icon
195
Vericel Corp
VCEL
$2.03B
– –
-9,385
Closed -$28K
XBI icon
196
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-50
Closed -$3K
ZTS icon
197
Zoetis
ZTS
$30.3B
– –
-3
Closed –
ENZ
198
DELISTED
Enzo Biochem, Inc.
ENZ
– –
-83,893
Closed -$582K
CTLT
199
DELISTED
CATALENT, INC.
CTLT
– –
-3
Closed –
PMD
200
DELISTED
Psychemedics Corporation
PMD
– –
-6,626
Closed -$164K
6 7
8
9 10

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.